883107-58-2 Usage
Uses
Used in Pharmaceutical Industry:
2-Benzyloxy-6-methylaniline is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into various drug molecules, contributing to the development of new medications.
Used in Agrochemical Industry:
2-Benzyloxy-6-methylaniline is used as a precursor in the production of agrochemicals, where it can be utilized to create compounds that aid in pest control and crop protection.
Used in Dye Industry:
2-Benzyloxy-6-methylaniline is used in the synthesis of dyes, where its chemical structure allows for the creation of a range of colored compounds for various applications.
Used in Organic Chemical Production:
2-Benzyloxy-6-methylaniline is used as an intermediate in the production of other organic chemicals, highlighting its versatility in chemical synthesis and compound development.
Safety Measures:
2-Benzyloxy-6-methylaniline is considered to be hazardous, as it may cause skin and eye irritation. Therefore, it should be handled with appropriate safety measures to minimize potential health risks.
Check Digit Verification of cas no
The CAS Registry Mumber 883107-58-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,3,1,0 and 7 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 883107-58:
(8*8)+(7*8)+(6*3)+(5*1)+(4*0)+(3*7)+(2*5)+(1*8)=182
182 % 10 = 2
So 883107-58-2 is a valid CAS Registry Number.
883107-58-2Relevant academic research and scientific papers
BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS
-
, (2018/05/27)
The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.
CGRP antagonists
-
Page/Page column 13, (2010/11/26)
The present invention encompasses compounds of Formula I which are antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and t
